Your session is about to expire
What is Tagrisso
OsimertinibThe Generic name of this drug
Treatment SummaryOsimertinib is an oral medication used to treat metastatic non-small cell lung cancer (NSCLC) that has spread despite treatment with other EGFR-TKIs. Around 10% of NSCLC patients have a mutation in their EGFR gene that makes them respond well to this type of drug. This third-generation EGFR-TKI is more specific than previous generations and less toxic, as it only targets the T790M mutation and spares wild-type EGFR.
Tagrissois the brand name
Tagrisso Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tagrisso
Osimertinib
2015
2
Approved as Treatment by the FDA
Osimertinib, also known as Tagrisso, is approved by the FDA for 5 uses which include Failed Tyrosine Kinase Inhibitors and Chemotherapy .Failed Tyrosine Kinase Inhibitors
Chemotherapy
Malignant Neoplasms
Non-Small Cell Lung Cancer
Pharmacotherapy
Effectiveness
How Tagrisso Affects PatientsA study found that taking osimertinib 80 mg can lead to a 14 millisecond (msec) increase in the QTc interval. However, the upper limit of this increase could be up to 16 msec.
How Tagrisso works in the bodyOsimertinib is a drug used to treat non-small cell lung cancer in people with certain mutations in the EGFR gene. It is a type of tyrosine kinase inhibitor (TKI) that specifically targets the T790M mutation, which is associated with a poor prognosis. It has 200 times more affinity for this mutation than for the normal, or wild-type, EGFR gene. Osimertinib is also less likely to bind to the wild-type EGFR, reducing the risk of side effects.
When to interrupt dosage
The prescribed dosage of Tagrisso is dependent on the diagnosed condition. The exact amount varies, in accordance with the method of administration specified in the table below.Condition
Dosage
Administration
Chemotherapy
40.0 mg, , 80.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Pharmacotherapy
40.0 mg, , 80.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Non-Small Cell Lung Cancer
40.0 mg, , 80.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Malignant Neoplasms
40.0 mg, , 80.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Failed Tyrosine Kinase Inhibitors
40.0 mg, , 80.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Warnings
There are 20 known major drug interactions with Tagrisso.Common Tagrisso Drug Interactions
Drug Name
Risk Level
Description
Ozanimod
Major
Osimertinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.
Rimegepant
Major
The serum concentration of Rimegepant can be increased when it is combined with Osimertinib.
(R)-warfarin
Moderate
The serum concentration of (R)-warfarin can be decreased when it is combined with Osimertinib.
3,5-Diiodotyrosine
Moderate
The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Osimertinib.
3,5-diiodothyropropionic acid
Moderate
The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Osimertinib.
Tagrisso Toxicity & Overdose RiskIn clinical trials, 3.7% of patients reported lung problems, including fatal cases in 0.3% of patients. There is also a risk of abnormal heart rhythm, so an electrocardiogram and electrolytes should be monitored for those with a history of abnormal heart rhythms. Additionally, 3% of patients reported heart muscle damage, so it is important to measure the left ventricular ejection fraction at the beginning and during treatment. Women should also be aware that osimertinib can cause harm to unborn babies and should use effective birth control during and after treatment.
Tagrisso Novel Uses: Which Conditions Have a Clinical Trial Featuring Tagrisso?
Nine active clinical trials are presently underway to evaluate the potential of Tagrisso in treating Malignant Neoplasms.Condition
Clinical Trials
Trial Phases
Failed Tyrosine Kinase Inhibitors
0 Actively Recruiting
Malignant Neoplasms
12 Actively Recruiting
Phase 3, Phase 1, Phase 2
Chemotherapy
2 Actively Recruiting
Not Applicable
Non-Small Cell Lung Cancer
350 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Pharmacotherapy
0 Actively Recruiting
Tagrisso Reviews: What are patients saying about Tagrisso?
5Patient Review
1/13/2019 My mom has been taking this treatment for 2.5 years and it's really helped her. She started with Tarceva and then switched to Targrisso after 18 months.
5Patient Review
7/17/2017 I had been taking Tarceva for ten years and it stopped working. My CEA score started rising, so I began Tagrisso in January 2017. Unfortunately, my heart started beating too fast.
5Patient Review
2/14/2017 Tarceva worked for me for six months, and then Optivo for two. Now Tegrisso is showing great improvement in my scans and tumor markers.
1.7Patient Review
12/19/2018 My father died after taking this medication for only three weeks.
Patient Q&A Section about tagrisso
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Can Tagrisso cure lung cancer?
"AstraZeneca's Tagrisso has been approved by the US Food and Drug Administration (FDA) for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent."
Answered by AI
What kind of cancer does Tagrisso treat?
"Tagrisso is a cancer medication used to treat non-small cell lung cancer (NSCLC). It is specifically used to treat patients whose cancer cells have certain mutations in the EGFR gene."
Answered by AI
Is Tagrisso a form of chemotherapy?
"TAGRISSO is a targeted cancer therapy in pill form that is taken once a day, with or without food. Targeted cancer therapies are designed specifically to target certain types of cancer and work by blocking the growth and spread of cancer cells."
Answered by AI